ArticleMolecular medicine reports2019
Exendin‑4 promotes osteogenic differentiation of adipose‑derived stem cells and facilitates bone repair.
Article in Molecular medicine reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 17 citations in OpenAlex.
- Glucagon-like peptide-1: a new potential regulator for mesenchymal stem cells in the treatment of type 2 diabetes mellitus and its complication.Stem cell research & therapy · 2025Review
- Semaglutide promotes the proliferation and osteogenic differentiation of bone-derived mesenchymal stem cells through activation of the Wnt/LRP5/β-catenin signaling pathway.Frontiers in pharmacology · 2025Article
- FKBP5 Regulates the Osteogenesis of Human Adipose-derived Mesenchymal Stem Cells.Current medical science · 2024Article
- Effects of Incretin Therapy on Skeletal Health in Type 2 Diabetes-A Systematic Review.JBMR plus · 2023Review
- Exendin-4 regulates the MAPK and WNT signaling pathways to alleviate the osteogenic inhibition of periodontal ligament stem cells in a high glucose environment.Open medicine (Warsaw, Poland) · 2023Article
- hUCMSCs carrying exenatide prevent T1DM by improving intestinal microflora composition and islet tissue damage repair.Molecular medicine (Cambridge, Mass.) · 2022Article
- Construction and performance of exendin-4-loaded chitosan-PLGA microspheres for enhancing implant osseointegration in type 2 diabetic rats.Drug delivery · 2022Article
- Current applications of adipose-derived mesenchymal stem cells in bone repair and regeneration: A review of cell experiments, animal models, and clinical trials.Frontiers in bioengineering and biotechnology · 2022Review
- Mineralized collagen scaffold bone graft accelerate the osteogenic process of HASCs in proper concentration.Regenerative therapy · 2021Article
- Current evidence on potential of adipose derived stem cells to enhance bone regeneration and future projection.World journal of stem cells · 2021Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammation‑related bone defects pose a heavy burden on patients and orthopedic surgeons. Although stem‑cell‑based bone repair has developed rapidly, it is of great significance to characterize bio‑active molecules that facilitate bone regeneration. It is reported that a glucagon‑like peptide 1 receptor agonist, exendin‑4, promoted bone regeneration mediated by the transplantation of adipose‑derived stem cells in a metaphyseal defect mouse model of femur injury. However, the underlying mechanism is unclear. Bone imaging, immunohistochemistry real‑time PCR and western blot analysis were used in the present study, and the results revealed that exendin‑4 increased the transcription of the osteogenic differentiation‑related genes and induced osteogenic differentiation in situ. Furthermore, the present data obtained from sorted adipose‑derived stem cells revealed that exendin‑4 promoted osteogenic differentiation and inhibited adipogenic differentiation in vitro. These findings indicated that exendin‑4 facilitates osteogenic differentiation of transplanted adipose‑derived stem cells for bone repair and illuminated clinical prospects of both adipose‑derived stem cells and exendin‑4 in stem‑cell‑based bone defect repair.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.